Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Elsevier's MEDalternatives Offers Additional Cost Saving Options For Payers And Members

Stock quotes in this article: ENL, RUK 

TAMPA, Florida, February 6, 2013 /PRNewswire/ --

New comprehensive resource for drug therapy options and costs helps health plan payers and members save on drug spend with information on alternative therapies

Elsevier's Gold Standard, a leading drug information provider, today announced the launch of the MEDalternatives™ database, a comprehensive resource for drug therapy options designed to give health plans and their members additional drug cost savings options through access to information on alternative therapies. MEDalternatives uses only evidence-based alternatives that have comparable or better efficacy and safety, compared to current prescriptions.

MEDalternatives covers a broad range of health conditions and the widest scope of medications, including a complete offering of drugs, drug classes, and product formulations. It returns alternatives within the class of the patient's current medication and across classes, including both generics and brands, and also provides therapeutically appropriate choices among subclasses of drugs.

MEDalternatives includes complete dosing options to ensure accurate comparisons in daily/weekly regimens and monthly/yearly costs, including those for in-store purchase versus mail-order delivery.

"MEDalternatives delivers a unique payer solution that identifies safe and cost- effective medication alternatives for achieving therapy compliance and prescription cost savings," said Marianne Messer, President, Elsevier's Gold Standard. "This will help our payer and PBM clients reduce prescription drug costs, particularly those who have already maximized their brand-to-generic switching, and improve medication adherence."

MEDalternatives helps:

  • Simplify drug regimens and drive down costs for payers and patients
  • Improve compliance for healthier and less expensive outcomes
  • Payers control prescription costs by offering therapeutic alternatives on brand-to-brand drugs, as well as brand-to-generic drugs
  • Payers educate providers and members on where savings can be attained on drugs
  • PBMs (Pharmacy Benefit Managers) enforce formulary compliance
  • Help providers identify alternative therapies to reduce costs
  • Guide consumers toward more affordable, safer and more effective medication options
  • Involve consumers in these choices, knowing that cost and convenience play a central role in adherence to treatment
  • Prepare consumers to discuss options with their healthcare providers
  • Boost patients' satisfaction with their drug benefits

MEDalternatives is derived from the most technologically sophisticated drug database available today and will easily integrate within and across diverse healthcare systems.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,387.58 52.30 0.34%
NASDAQ 3,502.12 5.69 0.16%
S&P 500 1,669.16 2.87 0.17%
US 10 Yr 1.944% -0.021

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs